Medical technology company eNeura Inc. announced on Friday that it has secured the inclusion of its SAVI Dual sTMS Neuromodulation treatment in Recon Supply's Federal Supply Schedule (FSS) contract.
This move enhances access to non-invasive migraine therapy for veterans, active-duty military and other federal healthcare beneficiaries. The FDA-cleared SAVI Dual sTMS offers a portable, patient-controlled, medication-free alternative for acute migraines and prevention.
Key federal agencies, including the Department of Veterans Affairs, Department of Defense and Indian Health Services, can now procure the treatment at negotiated pricing. Streamlined access to this innovative solution supports efforts to address migraines among millions of Americans, including military personnel and veterans. This milestone underscores eNeura Inc.'s commitment to advancing migraine care.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval